Puma Biotechnology

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2010-01-01

Employees: 185

Market Cap: $124.5M

Website: http://www.pumabiotechnology.com

Introduction: Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.

Clinical Trials

A Study Of Neratinib (HKI-272) And Capecitabine In Japanese With Solid Tumor

Phase 1

Completed

Conditions: Advanced Malignant Solid Tumors

Interventions: Drug: Neratinib
Drug: Capecitabine

First Posted Date: 2010-05-24

Last Posted Date: 2018-12-19

Lead Sponsor: Puma Biotechnology, Inc.

Target Recruit Count: 7

Registration Number: NCT01128842

Locations: 🇯🇵
Investigational Site, Tokyo, Japan

Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: Temsirolimus
Drug: Neratinib

First Posted Date: 2010-04-28

Last Posted Date: 2018-09-26

Lead Sponsor: Puma Biotechnology, Inc.

Target Recruit Count: 99

Registration Number: NCT01111825

Locations: 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇪🇸
Hospital Universitario Vall d'Hebron, Barcelona, Spain
🇺🇸
Western Regional Medical Center, Inc., Goodyear, Arizona, United States

and more 9 locations

Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Advanced Malignant Solid Tumors

Interventions: Drug: Neratinib
Drug: Vinorelbine

First Posted Date: 2009-08-13

Last Posted Date: 2018-06-28

Lead Sponsor: Puma Biotechnology, Inc.

Target Recruit Count: 6

Registration Number: NCT00958724

Locations: 🇯🇵
Shizuoka Cancer Center, Shizuoka, Japan
🇯🇵
The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan

Study Evaluating The Effect Of A High-Fat Meal On The Pharmacokinetics Of Neratinib

Phase 1

Withdrawn

Conditions: Healthy

Interventions: Drug: Neratinib

First Posted Date: 2009-07-03

Last Posted Date: 2012-05-14

Lead Sponsor: Puma Biotechnology, Inc.

Registration Number: NCT00932464

Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Neratinib
Drug: Trastuzumab
Drug: Paclitaxel

First Posted Date: 2009-06-05

Last Posted Date: 2018-08-22

Lead Sponsor: Puma Biotechnology, Inc.

Target Recruit Count: 479

Registration Number: NCT00915018

Locations: 🇫🇷
Service d'Oncologie et de Radiotherapie, Polyclinique Francheville, Perigueux, France
🇷🇴
Institutul Oncologic Prof. Dr. Ion Chiricuţă, Cluj-Napoca, Cluj, Romania
🇪🇸
Hospital Universitario Fundación Alcorcón, Alcorcon, Madrid, Spain

and more 191 locations

Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: neratinib
Other: placebo

First Posted Date: 2009-04-09

Last Posted Date: 2021-06-11

Lead Sponsor: Puma Biotechnology, Inc.

Target Recruit Count: 2840

Registration Number: NCT00878709

Locations: 🇺🇸
Mercy Hospital Oncology/Hematology Center, Portland, Maine, United States
🇺🇸
Cancer Specialists of South Texas, P.A., Corpus Christi, Texas, United States
🇺🇸
University Hospitals, Cleveland Medical Center, Cleveland, Ohio, United States

and more 482 locations

Study Evaluating The Potential Effect Of Rifampin On The Pharmacokinetics Of Neratinib

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: Neratinib

First Posted Date: 2009-03-18

Last Posted Date: 2012-05-14

Lead Sponsor: Puma Biotechnology, Inc.

Target Recruit Count: 24

Registration Number: NCT00864487

Study Evaluating The Potential Effect Of Multiple Doses Of Neratinib On The Pharmacokinetics Of A Single Dose Of Digoxin

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Digoxin
Drug: Neratinib

First Posted Date: 2009-03-12

Last Posted Date: 2012-05-14

Lead Sponsor: Puma Biotechnology, Inc.

Target Recruit Count: 27

Registration Number: NCT00860223

Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors

Phase 1

Completed

Conditions: Neoplasms
Malignant Carcinoma

Interventions: Drug: Neratinib
Drug: Temsirolimus

First Posted Date: 2009-02-06

Last Posted Date: 2018-09-18

Lead Sponsor: Puma Biotechnology, Inc.

Target Recruit Count: 63

Registration Number: NCT00838539

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇫🇷
Institut Gustave Roussy, Villejuif, France

and more 1 locations

Study Evaluating TwoTablet Formulations of Neratinib (HKI-272)

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: neratinib

First Posted Date: 2008-12-23

Last Posted Date: 2012-05-14

Lead Sponsor: Puma Biotechnology, Inc.

Target Recruit Count: 24

Registration Number: NCT00814060

Home Terms & Conditions Privacy Policy